Please assess the completion status of the following clinical trial:

Trial Title: Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathology confirmed solid tumors~* Failed to standard treatment or no standard treatments for uncontrolled, recurrent and/or metastatic advance tumor (whatever previous surgery conditions)~Dose-escalation stage:~\<300mg/day cohort no requiremnet for pathological pattern \>300mg/day cohort required NCSLC, head and net squamous carcinoma, or oesophageal carcinoma Dose-expansion stage required oesophageal carcinoma~* Age 18-75~* performance status of 0, or 1, and no worse within 7days~* Life expected \>3 months~* written informed consent form voluntarily~Exclusion Criteria:~* Lab testing within 1 week before enrolled, hemoglobin \<9 g/dL or , platelet count \< 750,000/mm3 and\<150000/mm3,~* Total bilirubin≥1.5× the upper limit of normal,~* Serum creatinine higher than normal range~* Diastolic pressure≥150mmHg or systolic pressure≥100mmHg whatever anti-hypertension drug used,~* Serum potassium (whenever potassium implemented) , serum calcium(ionic or albumin-type calcium) or serum magnesium outside normal ranges(whenever implemented)~* Within previous 4 weeks treated by systemic anti-tumor therapy, or radiotherapy, immune therapy, biological or hormonal therapy, and clinical trials. But exclude the below therapy, Prostate cancer treated by hormonal therapy such as GnRH(gonadotropin-releasing hormone) analogue or antagonist Hormone replacement therapy or oral contraceptive Palliative radiotherapy for bone metastasis within 2 weeks~* Prior documental evidence of resistance to EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitors)~* Unrecovered from any previous therapy related toxicity to≤ CTCAE(Common Toxicity Criteria for Adverse Effects) 0 or 1or unrecovered from any previous surgery~* Any CNS(central nervous system) metastasis with uncontrolled symptoms~* Known dysphagia or drug malabsorption~* Active infections such as acute pneumonia, hepatitis B active period~* APTT (activated partial thromboplastin time) and/or INR(international normalized ratio), PT≥2 the upper limit of normal(not including patients treated by anticoagulation treatment)~* ocular surface diseases or dry eye syndrome~* skin disease with obvious symptoms and signs~* significant cardiovascular disease, including II-IV atrioventricular block, acute myocardial infarction within 6 months, significant angina or Coronary artery bypass graft~* Known existing interstitial lung disease~* Female patients who are pregnant or feeding, or childbearing potential patient with pregnant testing positive~* Any abnormal of clinical and laboratory so that patients unsuitable to attend the trial sine in the opinion of the investigator~* Patients unable to comply with the protocol since significant psychological or psychogenic abnormal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single Group Assignment (Type: EXPERIMENTAL): Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 7 dose cohorts,including120mg/160mg/200mg/220mg/300mg/400mg/500mg, QD in the dose escalation stage .

Based on this trial design, predict the completion outcome and termination type (if applicable).